Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200010/S024

Guardant360 CDx

Guardant Health, Inc. · Decision date Sep 4, 2026

FDA DECISIONP200010/S024

What did the FDA approve?

FDA records P200010/S024 as a supplement to PMA P200010, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Sep 4, 2026.

FDA approval order statement

Approval for expanding the indications for use to include a companion diagnostic claim for the detection of ESR1 mutations in patients with breast cancer who may benefit from treatment with ETCAMAH (camizestrant).
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Sep 4, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P200010/S024
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P200010. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200010/S024 received

    Application receipt date recorded by FDA.

  2. P200010/S024 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P200010. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200010

Product / regulatory recordCompanyPathwayDecision dateSource
Guardant Health, Inc.PMA approvalAug 7, 2020FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Guardant Health, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
505 Penobscot Dr., Redwood City, CA, 94063

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records